Isomorphic Labs 完成 50 亿美元融资
Demis Hassabis 的 Isomorphic Labs 拿下 50 亿美元融资,专攻 AI 药物设计。和普通 AI 制药公司不同,它背后有 AlphaFold 的技术积累。做生物医药或关注 AI for Science 的朋友可以看看资本对这条赛道的判断。
Demis Hassabis 宣布其创立的 Isomorphic Labs 完成 50 亿美元融资,目标是加速推进“解决所有疾病”的使命。该公司正用 AI 从第一性原理重新设计药物研发流程,目标是大幅缩短新药发现的时间和成本。Hassabis 也是 Google DeepMind 的负责人,AlphaFold 蛋白质结构预测技术即出自其团队,这项技术正是 Isomorphic Labs 药物设计能力的核心基础。
本轮融资规模在 AI for Science 领域属于头部水平,显示资本愿意为长周期、高投入的药物研发下注。对药企和生物医药创业者而言,AI 驱动的 first principles 药物设计正在从论文走向工程化落地,研发管线的时间成本结构可能被重新定义。
Demis is a genius and will help push humanity forward. Demis Hassabis @demishassabis Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...
This report is categorized under AITOP's "Industry" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows. Key entities and technical topics under continuous tracking include Isomorphic Labs, Demis Hassabis, AI drug discovery, drug discovery.
Source attribution: curated from Aravind Srinivas (@AravSrinivas).